Skip to content

Oxybuprocaine

DERMATOLOGICALS

Also known as: benoxinate, benoxinate HCl, benoxinate hydrochloride, oxybucaine

OfpFDA approvedATC D04AB03ATC S01HA02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Oxybuprocaine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2020. DrugCentral lists 2 molecular targets, including SCN1A|SCN2A|SCN3A and SCN10A. Recorded indications include Topical local anesthetic to eye.

  • Approval status: ofp (first approved 2020 by the FDA).
  • Molecular targets: SCN1A|SCN2A|SCN3A and SCN10A (2 listed in DrugCentral).
  • Indications: Topical local anesthetic to eye.
  • ATC code: D04AB03 (Anesthetics for topical use).
  • Molecular formula: C17H28N2O3; molecular weight 308.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Topical local anesthetic to eye

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Sodium channel alpha subunits; brain (Types I, II, III)SCN1A|SCN2A|SCN3AblockerIC50 5.54
Sodium channel protein type 10 subunit alphaSCN10Ablocker—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2020-03-09FDA—BAUSCH

ATC classification

ATC codeTherapeutic hierarchy
D04AB03DERMATOLOGICALS › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. › Anesthetics for topical use
S01HA02SENSORY ORGANS › OPHTHALMOLOGICALS › LOCAL ANESTHETICS › Local anesthetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Toxic anterior segment syndrome308.0
Aqueous fibrin177.5
Non-infectious endophthalmitis122.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Oxybuprocaine is on its molecule page.

Molecular formulaC17H28N2O3
Molecular weight308.42 g/mol
CAS number99-43-4
InChIKeyCMHHMUWAYWTMGS-UHFFFAOYSA-N
PubChem CID4633
CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Oxybuprocaine used for?

DrugCentral lists the following indications for Oxybuprocaine: Topical local anesthetic to eye.

How does Oxybuprocaine work?

Its molecular targets in DrugCentral include SCN1A|SCN2A|SCN3A (blocker) and SCN10A (blocker).

When was Oxybuprocaine first approved?

Oxybuprocaine was first approved by the FDA in 2020.

What is the chemical formula of Oxybuprocaine?

Oxybuprocaine has the molecular formula C17H28N2O3 and a molecular weight of 308.42 g/mol.

Browse: all drugs starting with O · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2020-03-09
AgencyFDA
Targets2
Indications1
FormulaC17H28N2O3
DrugCentral ID3016
Interactive profile